Palovarotene Drug Shows Promise in Treating Rare Hereditary Disease

Palovarotene drug might keep multiple hereditary exostoses clinical feature, bony tumors at bay found a new study

Highlights

Palovarotene can now suppress the formation of bony tumors in Multiple Hereditary Exostoses (MHE) patients
Multiple osteochondromas is a hereditary genetic disorder in which many benign bone tumors grow at active areas of bone growth
Multiple hereditary exostoses is a rare genetic condition that affects about 1 in 50,000 people worldwide

Palovarotene drug can now suppress or decrease bony tumor (osteochondromas) formation in Multiple Hereditary Exostoses (MHE) models found a new study published in Journal of Bone and Mineral Research journal.

The research, is an important step toward an effective pharmacological treatment for MHE, a rare genetic condition that affects about 1 in 50,000 people worldwide.

Exostoses / Multiple Non-cancerous Bone Tumors - Causes, Symptoms, Diagnosis and Treatment
Hereditary multiple exostoses is a genetic disorder that causes skeletal abnormalities. Read on about its causes and symptoms and also how this symptom can be diagnosed and treated.

‘Multiple osteochondromas is a hereditary genetic disorder, caused mainly by mutations in two genes: EXT1 and EXT2. Individuals with these mutations develop painful, debilitating tumors, often repeatedly during their childhood and adolescence.’

MHE (also known as Multiple Osteochondromas, or MO) is an inherited genetic disorder in which multiple benign bone tumors covered with cartilage grow at active areas of bone growth.

The condition is caused by mutations in two genes: EXT1 and EXT2. Individuals with these mutations develop painful, debilitating tumors, often repeatedly during their childhood and adolescence. Surgery and pain management are currently the only treatment options for MHE patients.

"Our study shows that palovarotene is a remarkably potent inhibitor of osteochondromas", says Yu Yamaguchi, M.D., Ph.D., a professor at SBP.

Hip Replacement- Osteoarthritis, Post Operative Complications
Are you experiencing pain due to damaged hips? Travel abroad to get replacement surgery at affordable prices.

"In our mouse model of MHE, we were able to reduce bone tumors by more than 90 percent, which is a significant improvement over the previous drugs we have tested in the same mouse model." "Especially promising is that palovarotene has been tested for toxicity and side effects in humans and has been shown to be well tolerated," says Yamaguchi. "This means that timeline for getting the drug to the clinic for MHE may be shortened."

Clementia Pharmaceuticals licensed palovarotene from Roche Pharmaceuticals, which previously investigated the compound as a possible treatment for chronic pulmonary disease and evaluated its safety in more than 800 healthy volunteers and patients. Clementia Pharmaceuticals is planning to initiate a Phase 2/3 clinical trial in 2018 for patients with MHE.

Carcinoid Tumors - Carcinoid Syndrome - Symptoms, Signs, Diagnosis & Treatment
Carcinoid tumors is a benign tumor that results in carcinoid syndrome. Only 8 to 10% of all carcinoid tumors are associated with the carcinoid syndrome.

"This is the first time we are seeing a clear path toward a therapy that will improve the lives of MHE patients and their families," says Sarah Ziegler, vice-president of the MHE Research Foundation.

"The long-awaited first clinical trial for a drug to treat MHE is now a reality. This breakthrough comes after years of working with medical professionals and scientists like Dr. Yamaguchi to achieve something we have all been desperately striving for, for many years."

Pituitary Tumors - Causes, Symptoms, Diagnosis, Treatment
How do pituitary tumors affect you and what are the risks, symptoms and causes of pituitary tumors? Read on how pituitary tumors affect the quality of your life and just how effective is treatment.

Reference

Toshihiro Inubushi, Isabelle Lemire, Fumitoshi Irie, Yu Yamaguchi. Palovarotene inhibits osteochondroma formation in a mouse model of multiple hereditary exostoses, Journal of Bone and Mineral Research (2017).DOI: 10.1002/jbmr.3341

Source-Eurekalert